Related Concept Videos
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma.
Nature medicine·2026
Same author
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.
bioRxiv : the preprint server for biology·2025
Same author
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.
Journal of hematology & oncology·2025
Same author
Timing Genomic Antigen Loss in Multiple Myeloma Treated with T Cell-Redirecting Immunotherapies.
Blood cancer discovery·2025
Same author
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.
Blood·2025
Same journal
Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.
Blood·2026
Same journal
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.
Blood·2026
Same journal
Single Cell Analysis of the Tumor Microenvironment Landscape Across the Disease Spectrum of Multiple Myeloma.
Blood·2026
Same journal
How I Treat Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists.
Blood·2026